Placeholder Banner

BIO Comments on REMS Assessment: Planning and Reporting

April 2, 2019

BIO submitted comments to the Food and Drug Administration (FDA) on the draft guidance, REMS Assessment: Planning and Reporting

BIO says the guidance offers clear, practical information to sponsors and other stakeholders involved in the design and effectiveness evaluation of REMS programs. It provides instrumental recommendations, particularly on how the REMS program goals, objectives, and design may impact the selection of metrics and data sources, which will be used to assess whether the program is meeting its risk mitigation goals.

BIO requests clarifications, particularly on how existing REMS would be grandfathered and evaluation of the burden on healthcare system and patient access. In addition, BIO would welcome the opportunity to partner with the FDA to define improved metrics to evaluate safety-related health outcomes. 

Download Full Comments Below
FINAL BIO Letter REMS Assessment Planning And Reporting
Read full comment letter below
Discover More
March 18, 2020 FDA Docket No: FDA-2019-D-4964: FDA Draft Guidance on Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products Dear Sir/Madam: BIO thanks FDA for developing this additional guidance on…
March 15, 2020 Re: Docket No. FDA–2019-D-4752: FDA Draft Guidance, Pediatric Study Plans for Oncology Drugs: Questions and Answers BIO appreciates FDA’s efforts to develop a document that outlines questions and answers pertaining to Pediatric…
In the wake of the COVID-19 outbreak, the Biotechnology Innovation Organization (BIO) joins 111 industry groups across sectors in a letter to federal, state and local lawmakers supporting uniform definitions of "critical infrastructure" as outlined…